CN114712554A - Full-bio-based Angelica keiskei antibacterial hydrogel and preparation method thereof - Google Patents
Full-bio-based Angelica keiskei antibacterial hydrogel and preparation method thereof Download PDFInfo
- Publication number
- CN114712554A CN114712554A CN202210420117.XA CN202210420117A CN114712554A CN 114712554 A CN114712554 A CN 114712554A CN 202210420117 A CN202210420117 A CN 202210420117A CN 114712554 A CN114712554 A CN 114712554A
- Authority
- CN
- China
- Prior art keywords
- angelica keiskei
- antibacterial
- solution
- antibacterial hydrogel
- bio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001105098 Angelica keiskei Species 0.000 title claims abstract description 93
- 239000000017 hydrogel Substances 0.000 title claims abstract description 75
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000000499 gel Substances 0.000 claims abstract description 40
- 239000007864 aqueous solution Substances 0.000 claims abstract description 30
- 239000011259 mixed solution Substances 0.000 claims abstract description 26
- 239000000243 solution Substances 0.000 claims abstract description 22
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims abstract description 22
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000000661 sodium alginate Substances 0.000 claims abstract description 21
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 21
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 21
- 238000003756 stirring Methods 0.000 claims abstract description 20
- 239000006228 supernatant Substances 0.000 claims abstract description 20
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 17
- XDVNRYBLLJRCFU-BTVCFUMJSA-N calcium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound [Ca].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDVNRYBLLJRCFU-BTVCFUMJSA-N 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 11
- 238000006243 chemical reaction Methods 0.000 claims abstract description 10
- 238000009792 diffusion process Methods 0.000 claims abstract description 10
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 238000005119 centrifugation Methods 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 8
- 239000012266 salt solution Substances 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 239000008176 lyophilized powder Substances 0.000 claims description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 9
- 239000001110 calcium chloride Substances 0.000 claims description 9
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 9
- 229960002713 calcium chloride Drugs 0.000 claims description 9
- 235000011148 calcium chloride Nutrition 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- 239000004227 calcium gluconate Substances 0.000 claims description 4
- 229960004494 calcium gluconate Drugs 0.000 claims description 4
- 235000013927 calcium gluconate Nutrition 0.000 claims description 4
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 4
- 239000001527 calcium lactate Substances 0.000 claims description 4
- 235000011086 calcium lactate Nutrition 0.000 claims description 4
- 239000001506 calcium phosphate Substances 0.000 claims description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 4
- 235000011010 calcium phosphates Nutrition 0.000 claims description 4
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 229940041131 calcium lactate gluconate Drugs 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 3
- 230000003385 bacteriostatic effect Effects 0.000 abstract description 5
- 238000004090 dissolution Methods 0.000 abstract description 2
- 241000588724 Escherichia coli Species 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- OYFLDJKOCDBXJS-FAOVPRGRSA-L calcium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;carbonate Chemical compound [Ca+2].[O-]C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O OYFLDJKOCDBXJS-FAOVPRGRSA-L 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 6
- 238000002791 soaking Methods 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 4
- 238000000635 electron micrograph Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- AEMOLEFTQBMNLQ-AZLKCVHYSA-N (2r,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-AZLKCVHYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-SYJWYVCOSA-N (2s,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-SYJWYVCOSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- GBYHQDUKBHZVSI-UHFFFAOYSA-N N-(dinitroamino)-N-(2,3-diphenylphenyl)nitramide Chemical compound C1(=CC=CC=C1)C=1C(=C(C=CC1)N(N([N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-])C1=CC=CC=C1 GBYHQDUKBHZVSI-UHFFFAOYSA-N 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229910021389 graphene Inorganic materials 0.000 description 1
- 239000008131 herbal destillate Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000854 inhibitional effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000002082 metal nanoparticle Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/04—Alginic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2397/00—Characterised by the use of lignin-containing materials
- C08J2397/02—Lignocellulosic material, e.g. wood, straw or bagasse
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention provides a preparation method of a full-biobased angelica keiskei antibacterial hydrogel, which comprises the following steps: s1: solution co-dissolution: dissolving the angelica keiskei natural antibacterial freeze-dried powder in a solvent, performing rotary centrifugation treatment, taking a supernatant, dropwise adding the supernatant into a sodium alginate aqueous solution, and stirring and mixing; s2: sol-gel treatment: adding a calcium salt-glucose caprolactone mixed solution into the solution treated in the step S1, carrying out sol-gel reaction, stirring, and standing for 3-5 hours to obtain primary gel; s3: and (3) external diffusion treatment: and (4) immersing the gel prepared in the step (S2) into a calcium salt solution to prepare the full-bio-based angelica keiskei antibacterial hydrogel. The full-bio-based Angelica keiskei antibacterial hydrogel prepared by the method has a strong bacteriostatic effect and has high commercial value and popularization value.
Description
Technical Field
The invention belongs to the field of medical high polymer materials, and particularly relates to a full-bio-based angelica keiskei antibacterial hydrogel and a preparation method thereof.
Background
Worldwide, a large number of wound dressings are available for the treatment of various types of wound wounds every year. China is the largest producing country of traditional medical dressings, such as cotton, bandages, gauze and the like. Although the traditional medical dressing has a long use history and has the advantages of good water absorption, good heat preservation performance, low price and the like, most of the traditional medical dressings do not have the antibacterial and bactericidal effects, and need to be replaced frequently in the use process to reduce bacterial infection. In addition, wound exudate absorbed by the traditional medical dressing is easy to separate out by secondary extrusion, which can cause secondary infection of the wound.
The high molecular hydrogel is a substance which is formed by crosslinking a water-soluble polymer through physical or chemical actions such as intermolecular ionic bond, covalent bond, hydrogen bond and the like and has a three-dimensional network structure, has the advantages of high water content, good moisture retention performance, high volume swelling ratio and the like, and is an ideal substitute material for the traditional medical wound dressing. In recent years, research on antibacterial hydrogel has been rapidly developed, for example, patents CN2015100460368 and CN2015108512939 disclose a polymer hydrogel based on poly (β -amino ester), and the inventors have realized the antibacterial performance of hydrogel by introducing nano silver or graphene oxide; patent CN2014103022002 adopts aldehyde cellulose and chitosan as hydrogel matrix, and antibacterial performance is imparted to hydrogel by adsorbing silver particles. Sui et al (Polymer Chemistry,2013,4: 337-. Although many reported polymer hydrogels for medical dressings show good moisturizing and antibacterial performances, most hydrogels adopt non-natural degradable polymer materials as hydrogel matrixes or realize a bactericidal function by introducing non-natural antibacterial components such as metal nanoparticles, quaternary ammonium salts and antibiotics, so that the polymer antibacterial hydrogels as wound healing dressings have certain environmental safety and biological safety risks.
Sodium alginate is a polysaccharide high molecular polymer derived from natural Sargassum, is a linear high molecular polymer prepared by combining poly beta-mannuronic acid and poly alpha-L-guluronic acid, is safe and nontoxic, and can be mixed with divalent metal ion such as Ca2+、Cu2+And the like, to form a hydrogel. The angelica keiskei is a herbaceous plant planted in China, and the seeds, stems and roots of the angelica keiskei contain a large amount of flavonoid active ingredients, so that the angelica keiskei has obvious antibacterial, anti-inflammatory and antioxidant effects and is a natural efficient antibacterial agent.
The effective antibacterial component in angelica keiskei is introduced into the sodium alginate hydrogel to prepare the full-bio-based antibacterial hydrogel completely derived from natural renewable resources, which has wide application prospect and value in the field of medical wound dressings, but at present, no mature technical scheme exists in the related fields.
Disclosure of Invention
The invention aims to solve the technical problems that the traditional medical wound dressing has poor antibacterial property and moisture retention performance, and the conventional high-molecular antibacterial hydrogel has potential environmental safety, biological safety risks and the like, and provides a preparation method of a full-biological-based Angelica keiskei antibacterial hydrogel.
In order to solve the problems, the invention provides a preparation method of a full-bio-based angelica keiskei antibacterial hydrogel, which comprises the following steps:
s1: co-dissolving the solution: dissolving the angelica keiskei natural antibacterial freeze-dried powder in a solvent, performing rotary centrifugation treatment, taking a supernatant, dropwise adding the supernatant into a sodium alginate aqueous solution, and stirring and mixing;
s2: sol-gel treatment: adding a calcium salt-glucose caprolactone mixed solution into the solution treated in the step S1, carrying out sol-gel reaction, stirring, and standing for 3-5 hours to obtain primary gel;
s3: and (3) external diffusion treatment: and (4) immersing the initial gel prepared in the step (S2) into a calcium salt solution to prepare the full-bio-based Angelica keiskei antibacterial hydrogel.
Preferably, in step S1, the natural antibacterial lyophilized powder of angelica keiskei is one or more of lyophilized powder of angelica keiskei leaf, lyophilized powder of angelica keiskei stem, and lyophilized powder of angelica keiskei root.
Preferably, in step S1, the solvent is one or more of ethanol, acetone, dimethylformamide and dimethylsulfoxide.
Preferably, in step S1, the conditions of the spin centrifugation are: spin-centrifuge at 5000rpm for 5 min.
Preferably, in step S1, the concentration of the sodium alginate aqueous solution is 0.1-5 wt%.
Preferably, in step S2, the calcium salt is one or more of calcium carbonate, calcium sulfate and calcium phosphate; the calcium salt-glucose caprolactone mixed solution is an aqueous solution, and the content of the calcium salt-glucose caprolactone mixed solution in the aqueous solution is 10-100 mmol/L.
Preferably, in the step S1 and the step S2, the volume ratio of the sodium alginate aqueous solution to the calcium salt-glucose caprolactone mixed solution is (10-1): 1.
preferably, in step S3, the calcium salt is one or more of calcium chloride, calcium lactate and calcium gluconate, and the concentration of the calcium salt solution is 4%.
Preferably, in step S3, the immersion time is 1-10 h.
The invention aims to solve another technical problem that: provides a full-biobased angelica keiskei antibacterial hydrogel, which solves the problems that most of the traditional medical dressings do not have antibacterial and bactericidal effects and need to be replaced frequently in the using process so as to reduce bacterial infection.
In order to solve the problems, the invention provides a full-bio-based angelica keiskei antibacterial hydrogel which is prepared by any one of the preparation methods.
Compared with the traditional medical wound dressing and the conventional high-molecular antibacterial hydrogel, the full-biobased Angelica keiskei antibacterial hydrogel has the following remarkable beneficial effects:
1) all raw materials come from nature, are natural, green and degradable and renewable;
2) the prepared full-bio-based Angelica keiskei antibacterial hydrogel has an obvious bactericidal effect on gram-positive bacteria (staphylococcus aureus) and gram-negative bacteria (escherichia coli), the bactericidal rate on staphylococcus aureus is more than 98%, and the bactericidal rate on escherichia coli is more than 96%;
3) the prepared full-bio-based angelica keiskei antibacterial hydrogel has obvious antioxidant activity, and the free radical trapping rate of the hydrogel on diphenyl trinitrophenyl hydrazine DPPH is up to more than 90%;
the preparation method of the full-bio-based Angelica keiskei antibacterial hydrogel provided by the invention is simple in preparation process, good in repeatability and easy to realize large-scale production.
Drawings
FIG. 1 is an electron micrograph of a hydrogel of Angelica keiskei root;
FIG. 2 is an electron micrograph of a hydrogel of the leaf of Angelica keiskei;
FIG. 3 is an electron micrograph of a hydrogel of Angelica keiskei stem;
FIG. 4 is a graph of the inhibition zone of hydrogel of Angelica keiskei Koidz on Staphylococcus aureus;
FIG. 5 is a plot of the inhibition zone of hydrogel of Angelica keiskei Koidz leaf on Escherichia coli;
fig. 6 is a line graph showing comparison of DPPH radical trapping and killing rates of different angelica keiskei hydrosols, and fig. 6 shows concentration-DPPH radical inhibitory activity change curves of an angelica keiskei leaf, an angelica keiskei root and an angelica keiskei stem in the order from top to bottom when the concentration is 1000 um/mL.
Detailed Description
The technical solutions of the present invention will be described clearly and completely below, and it should be apparent that the described embodiments are some, but not all, embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The invention provides a preparation method of a full-biobased angelica keiskei antibacterial hydrogel, which comprises the following steps:
s1: co-dissolving the solution: dissolving the angelica keiskei natural antibacterial freeze-dried powder in a solvent, performing rotary centrifugation treatment, taking a supernatant, dropwise adding the supernatant into a sodium alginate aqueous solution, and stirring and mixing;
s2: sol-gel treatment: adding a calcium salt-glucose caprolactone mixed solution into the solution treated in the step S1, carrying out sol-gel reaction, stirring, and standing for 3-5 hours to obtain primary gel;
s3: and (3) external diffusion treatment: and (4) immersing the initial gel prepared in the step (S2) into a calcium salt solution to prepare the full-bio-based Angelica keiskei antibacterial hydrogel.
Preferably, in step S1, the natural antibacterial lyophilized powder of angelica keiskei is one or more of lyophilized powder of angelica keiskei leaf, lyophilized powder of angelica keiskei stem, and lyophilized powder of angelica keiskei root.
Preferably, in step S1, the solvent is one or more of ethanol, acetone, dimethylformamide and dimethylsulfoxide.
Preferably, in step S1, the conditions of the spin centrifugation are: spin-centrifuge at 5000rpm for 5 min.
Preferably, in the step S1, the concentration of the sodium alginate aqueous solution is 0.1-5 wt%, and the preferred concentration is 1 wt%.
Preferably, in step S2, the calcium salt is one or more of calcium carbonate, calcium sulfate and calcium phosphate; the calcium salt-glucose caprolactone mixed solution is an aqueous solution, and the content of the calcium salt-glucose caprolactone mixed solution in the aqueous solution is 10-100mmol/L, preferably 50 mmol/L.
Preferably, in the steps S1 and S2, the volume ratio of the sodium alginate aqueous solution to the calcium salt-glucose caprolactone mixed solution is (10-1): 1, preferably at a concentration of 3: 1.
preferably, in step S3, the calcium salt is one or more of calcium chloride, calcium lactate and calcium gluconate, and the concentration of the calcium salt solution is 4%.
Preferably, in step S3, the immersion time is 1-10h, preferably 2 h.
The invention also provides the full-biobased angelica keiskei antibacterial hydrogel prepared by the preparation method.
Example 1:
a preparation method of a full-bio-based Angelica keiskei antibacterial hydrogel comprises the following steps:
s1: co-dissolving the solution: dissolving the angelica keiskei freeze-dried powder in ethanol, performing rotary centrifugation for 5min at 5000rpm, taking supernatant, dropwise adding the supernatant into 1 wt% sodium alginate aqueous solution, and continuously stirring until the mixture is uniformly mixed;
s2: sol-gel treatment: adding calcium carbonate-glucose caprolactone in a volume ratio of 3: 1 to the solution treated in the step S1, wherein the substance concentration of the mixed solution is 50mmol/L, and the volume ratio of the sodium alginate aqueous solution to the calcium carbonate-glucose caprolactone mixed solution is 3: 1, carrying out sol-gel reaction, stirring and standing for 3 hours to obtain primary gel;
s3: and (3) external diffusion treatment: and (4) soaking the gel prepared in the step (S2) into a 4 wt% calcium chloride aqueous solution for 2 hours to prepare the full-bio-based Angelica keiskei antibacterial hydrogel.
Example 2:
a preparation method of a full-bio-based Angelica keiskei antibacterial hydrogel comprises the following steps:
s1: co-dissolving the solution: dissolving the angelica keiskei freeze-dried powder in ethanol, performing rotary centrifugation at 5000rpm for 5min, taking supernatant, dropwise adding the supernatant into 5 wt% sodium alginate aqueous solution, and continuously stirring until the mixture is uniformly mixed;
s2: sol-gel treatment: adding calcium carbonate-glucose caprolactone in a volume ratio of 10: 1 to the solution treated in the step S1, wherein the substance concentration of the mixed solution is 100mmol/L, and the volume ratio of the sodium alginate aqueous solution to the calcium carbonate-glucose caprolactone mixed solution is 10: 1, carrying out sol-gel reaction, stirring and standing for 3 hours to obtain primary gel;
s3: and (3) external diffusion treatment: and (4) soaking the gel prepared in the step (S2) into a 4 wt% calcium chloride aqueous solution for 10 hours to prepare the full-bio-based Angelica keiskei antibacterial hydrogel.
Example 3:
a preparation method of a full-bio-based Angelica keiskei antibacterial hydrogel comprises the following steps:
s1: co-dissolving the solution: dissolving Angelica keiskei freeze-dried powder in ethanol, centrifuging at 5000rpm for 5min, collecting supernatant, adding the supernatant dropwise into 0.1 wt% sodium alginate water solution, and stirring continuously until mixing well;
s2: sol-gel treatment: adding a calcium carbonate-glucose caprolactone mixed solution into the solution treated in the step S1, wherein the mass concentration of the mixed solution is 10mmol/L, and the volume ratio of the sodium alginate aqueous solution to the calcium carbonate-glucose caprolactone mixed solution is 1: 1, carrying out sol-gel reaction, stirring and standing for 3 hours to obtain primary gel;
s3: and (3) external diffusion treatment: and (4) soaking the gel prepared in the step (S2) into a 4 wt% calcium chloride aqueous solution for 1 hour to prepare the full-bio-based Angelica keiskei antibacterial hydrogel.
Example 4:
the embodiment 4 is the same as the embodiment 1 in other conditions and steps, and is different in that in the step S1, the adopted lyophilized powder is the lyophilized powder of angelica keiskei koidz;
example 5:
example 5 is the same as example 1 in other conditions and steps, except that in step S1, the adopted lyophilized powder is lyophilized powder of angelica keiskei stem;
example 6:
example 6 is the same as example 1 in other conditions and steps, except that in step S1, acetone is used as the solvent, and in step S2, calcium sulfate is used as the calcium salt; in the step S3, the adopted calcium salt is calcium lactate;
example 6:
example 6 the same as example 1 except that in step S1, the solvent used was dimethylformamide, and in step S2, the calcium salt used was calcium phosphate; in the step S3, the calcium salt is calcium gluconate;
example 7:
example 7 was performed under the same conditions and in the same steps as example 1, except that dimethyl sulfoxide was used as the solvent in step S1.
The following examples are provided to explain the invention with specific reference to the actual data:
example 8:
a preparation method of a full-bio-based Angelica keiskei antibacterial hydrogel comprises the following steps:
s1: co-dissolving the solution: dissolving 100mg of Angelica keiskei freeze-dried powder in 3ml of ethanol, centrifuging at 5000rpm for 5min, collecting supernatant, adding the supernatant into 20ml of 1 wt% sodium alginate aqueous solution, and continuously stirring until mixing uniformly;
s2: sol-gel treatment: adding an isometric calcium carbonate-glucose caprolactone mixed solution (the concentration is 50mmol/L) to the solution treated in the step S1, wherein the mass concentration of the mixed solution is 100mmol/L, carrying out sol-gel reaction, stirring, and standing for 3 hours to obtain primary gel;
s3: and (3) external diffusion treatment: and (4) soaking the gel prepared in the step (S2) into a 4 wt% calcium chloride aqueous solution for 2 hours to prepare the full-bio-based Angelica keiskei antibacterial hydrogel.
Example 9:
a preparation method of a full-bio-based Angelica keiskei antibacterial hydrogel comprises the following steps:
s1: solution co-dissolution: dissolving 100mg of Angelica keiskei stem lyophilized powder in 3ml of ethanol, centrifuging at 5000rpm for 5min, collecting supernatant, adding the supernatant into 20ml of 1 wt% sodium alginate aqueous solution, and stirring continuously until mixing;
s2: sol-gel treatment: adding an isometric calcium carbonate-glucose caprolactone mixed solution (the concentration is 50mmol/L) to the solution treated in the step S1, wherein the mass concentration of the mixed solution is 100mmol/L, carrying out sol-gel reaction, stirring, and standing for 3 hours to obtain primary gel;
s3: and (3) external diffusion treatment: and (4) soaking the gel prepared in the step (S2) into a 4 wt% calcium chloride aqueous solution for 2 hours to prepare the full-bio-based Angelica keiskei antibacterial hydrogel.
The hydrogel is subjected to a sterilization test of escherichia coli positive bacteria, and the sterilization rate of the hydrogel on the escherichia coli positive bacteria is 96%.
Example 10:
a preparation method of a full-bio-based angelica keiskei antibacterial hydrogel comprises the following steps:
s1: co-dissolving the solution: dissolving 100mg of Angelica keiskei leaf lyophilized powder in 3ml of ethanol, centrifuging at 5000rpm for 5min, collecting supernatant, adding the supernatant into 20ml of 1 wt% sodium alginate aqueous solution, and stirring continuously until mixing;
s2: sol-gel treatment: adding an isometric calcium carbonate-glucose caprolactone mixed solution (the concentration is 50mmol/L) to the solution treated in the step S1, wherein the mass concentration of the mixed solution is 100mmol/L, carrying out sol-gel reaction, stirring, and standing for 3 hours to obtain primary gel;
s3: and (3) external diffusion treatment: and (4) soaking the gel prepared in the step (S2) into a 4 wt% calcium chloride aqueous solution for 2 hours to prepare the full-bio-based Angelica keiskei antibacterial hydrogel.
The hydrogel is subjected to a sterilization test of escherichia coli positive bacteria, and the sterilization rate of the hydrogel on the escherichia coli positive bacteria is 96%; the hydrogel is subjected to a sterilization test of escherichia coli negative bacteria, and the sterilization rate of the hydrogel on the escherichia coli negative bacteria is 97%.
Observing the hydrogel prepared from the angelica keiskei koidzumi, the angelica keiskei koidzumi and the angelica keiskei stem in examples 8-10 by using an electron microscope, wherein the observation graphs are shown in figures 1, 2 and 3, and the hydrogel prepared from the angelica keiskei koidzumi of example 10 is subjected to a zone of inhibition test, including zone of inhibition tests of staphylococcus aureus and escherichia coli, and the test results are shown in figures 4 and 5, which can be obviously found from figures 4 and 5, the total bio-based angelica keiskei koidzumi antibacterial hydrogel disclosed by the invention can generate stronger inhibition effects on staphylococcus aureus and escherichia coli, which also proves that the total bio-based angelica keiskei koidzumi antibacterial hydrogel disclosed by the invention has higher inhibition and antibacterial effects, and the hydrogel prepared from the angelica keiskei koidzumi, the angelica keiskei koidzumi and the angelica keiskei stem of examples 8-10 disclosed by the invention is subjected to a DPPH radical capture rate test, the test result is shown in the graph drawn in fig. 6, and it can be seen from fig. 6 that the hydrogel prepared from the angelica keiskei koidz, the angelica keiskei koidz and the angelica keiskei koidz has bacteriostatic ability, and the hydrogel prepared from the angelica keiskei koidz has the strongest bacteriostatic effect, and reaches a better bacteriostatic effect when the concentration is 200mg/mL, while the angelica keiskei koidz and the angelica keiskei koidz need to have a better bacteriostatic effect under the condition of higher concentration.
Although the present disclosure has been described above, the scope of the present disclosure is not limited thereto. Those skilled in the art can make various changes and modifications without departing from the spirit and scope of the present disclosure, and such changes and modifications will fall within the scope of the present invention.
Claims (10)
1. A preparation method of a full-bio-based Angelica keiskei antibacterial hydrogel is characterized by comprising the following steps:
s1: co-dissolving the solution: dissolving the angelica keiskei natural antibacterial freeze-dried powder in a solvent for rotary centrifugation treatment, taking supernatant, dropwise adding the supernatant into a sodium alginate aqueous solution, and stirring and mixing;
s2: sol-gel treatment: adding a calcium salt-glucose caprolactone mixed solution into the solution treated in the step S1, carrying out sol-gel reaction, stirring, and standing for 3-5 hours to obtain primary gel;
s3: and (3) external diffusion treatment: and (4) immersing the initial gel prepared in the step (S2) into a calcium salt solution to prepare the full-bio-based Angelica keiskei antibacterial hydrogel.
2. The method for preparing the all-biobased angelica keiskei antibacterial hydrogel according to claim 1, characterized in that: in the step S1, the natural antibacterial lyophilized powder of angelica keiskei is one or more of lyophilized powder of angelica keiskei leaf, lyophilized powder of angelica keiskei stem and lyophilized powder of angelica keiskei root.
3. The method for preparing the all-bio-based angelica keiskei antibacterial hydrogel according to claim 1, which is characterized in that: in the step S1, the solvent is one or more of ethanol, acetone, dimethylformamide and dimethyl sulfoxide.
4. The method for preparing the all-biobased angelica keiskei antibacterial hydrogel according to claim 1, characterized in that: in step S1, the conditions of the spin centrifugation are: spin-centrifuge at 5000rpm for 5 min.
5. The method for preparing the all-biobased angelica keiskei antibacterial hydrogel according to claim 1, characterized in that: in the step S1, the concentration of the sodium alginate aqueous solution is 0.1-5 wt%.
6. The method for preparing the all-biobased angelica keiskei antibacterial hydrogel according to claim 1, characterized in that: in step S2, the calcium salt is one or more of calcium carbonate, calcium sulfate, and calcium phosphate; the calcium salt-glucose caprolactone mixed solution is an aqueous solution, and the content of the calcium salt-glucose caprolactone mixed solution in the aqueous solution is 10-100 mmol/L.
7. The method for preparing the all-biobased angelica keiskei antibacterial hydrogel according to claim 1, characterized in that: in the step S1 and the step S2, the volume ratio of the sodium alginate aqueous solution to the calcium salt-glucose caprolactone mixed solution is (10-1): 1.
8. the method for preparing the all-bio-based angelica keiskei antibacterial hydrogel according to claim 1, which is characterized in that: in step S3, the calcium salt is one or more of calcium chloride, calcium lactate, and calcium gluconate, and the concentration of the calcium salt solution is 4%.
9. The method for preparing the all-biobased angelica keiskei antibacterial hydrogel according to claim 1, characterized in that: in the step S3, the immersion time is 1-10 h.
10. An all-bio-based Angelica keiskei antibacterial hydrogel, which is prepared by the preparation method of any one of claims 1 to 9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210420117.XA CN114712554A (en) | 2022-04-20 | 2022-04-20 | Full-bio-based Angelica keiskei antibacterial hydrogel and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210420117.XA CN114712554A (en) | 2022-04-20 | 2022-04-20 | Full-bio-based Angelica keiskei antibacterial hydrogel and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114712554A true CN114712554A (en) | 2022-07-08 |
Family
ID=82245685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210420117.XA Pending CN114712554A (en) | 2022-04-20 | 2022-04-20 | Full-bio-based Angelica keiskei antibacterial hydrogel and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114712554A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140276493A1 (en) * | 2013-03-15 | 2014-09-18 | Braden King-Fung Leung | Wound healing compositions |
| CN108392672A (en) * | 2018-03-23 | 2018-08-14 | 曹朗翘 | Radix Notoginseng seaweed gel dressing and preparation method thereof |
| CN108785738A (en) * | 2018-06-22 | 2018-11-13 | 中南大学 | A kind of preparation method and applications of hydrogel medical dressing |
-
2022
- 2022-04-20 CN CN202210420117.XA patent/CN114712554A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140276493A1 (en) * | 2013-03-15 | 2014-09-18 | Braden King-Fung Leung | Wound healing compositions |
| CN108392672A (en) * | 2018-03-23 | 2018-08-14 | 曹朗翘 | Radix Notoginseng seaweed gel dressing and preparation method thereof |
| CN108785738A (en) * | 2018-06-22 | 2018-11-13 | 中南大学 | A kind of preparation method and applications of hydrogel medical dressing |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10426809B2 (en) | Nanobiocomposite formulation for wound healing and a process for the preparation thereof | |
| CN109200334B (en) | Composite hydrogel dressing for photodynamic therapy of wound infection and preparation method thereof | |
| CN101255274A (en) | Composite nano silver-polyurethane antibiotic material and preparation thereof | |
| CN112480434B (en) | Copper ion antibacterial hydrogel and preparation method and application thereof | |
| CN110522945B (en) | Medical biogel hemostatic dressing and preparation method thereof | |
| CN102406957A (en) | Preparation method of nano silver-containing sodium alginate wound dressing | |
| CN112451738B (en) | Silver ion polysaccharide polymer antibacterial dressing and preparation method and application thereof | |
| CN114984300B (en) | Tough antibacterial hydrogel dressing and preparation method thereof | |
| CN103074777A (en) | Silver-loaded alginate fiber and preparation method thereof | |
| CN112587717A (en) | Metal cation crosslinked alginate/bacterial cellulose composite hydrogel antibacterial dressing | |
| CN113679881A (en) | Medical dressing with antibacterial property and preparation method thereof | |
| CN111658815B (en) | Antibacterial alginate dressing and preparation method thereof | |
| CN114712554A (en) | Full-bio-based Angelica keiskei antibacterial hydrogel and preparation method thereof | |
| CN107441546B (en) | Preparation method of silver-containing antibacterial dressing | |
| CN107198789B (en) | Nano platinum polymer and preparation method and application thereof | |
| CN106947268B (en) | A kind of preparation method of silk gum/glycerol blend film and products thereof and application | |
| CN113005633A (en) | Antibacterial nanofiber membrane and preparation method and application thereof | |
| CN112724422B (en) | Antibacterial wheat straw cellulose composite hydrogel and preparation method and application thereof | |
| CN102058898B (en) | Powder with antibacterial and haemostatic effects and preparation method and applications thereof | |
| CN108210979B (en) | Medical bactericidal fiber dressing | |
| CN114000349B (en) | Alginate-encapsulated bacterial cellulose composite photothermal antibacterial medical dressing and preparation method thereof | |
| CN114796592B (en) | Preparation method of chitosan-based antibacterial gel | |
| CN112957520B (en) | Visible light catalytic antibacterial hydrogel dressing and preparation method thereof | |
| CN112521627B (en) | Preparation method of green composite hydrogel with slow-release type purification and sterilization functions | |
| CN115920144B (en) | Preparation method of antibacterial medical stainless steel mesh |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220708 |
|
| RJ01 | Rejection of invention patent application after publication |